Aratana nears approval for canine cancer vaccine

Aratana Therapeutics Inc.'s cancer immunotherapy drug for dogs gained a conditional license from the U.S. Department of Agriculture, the company announced Wednesday. To gain full licensure, Aratana (Nasdaq; PETX) will start another field study in early 2018. The vaccine initially will be available for purchase at 12 veterinary oncology practices participating in the study. It's designed to treat dogs with bone cancer after the tumor is surgically removed. It works using listeria, a type of bacteria,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

Where are we currently on vaccines to prevent group A streptococcal infections? Get up-to-date on the recent progress.Current Opinion in Infectious Diseases
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Infectious Diseases Journal Article Source Type: news
Publication date: Available online 30 May 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Renjie Wang, Zhengwei Cao, Lan Wei, Lin Bai, Hui Wang, Shiyi Zhou, Shuyue Zhan, Bin Ji, Zibo Li, Shi Gao, Jin Xie, Qingjie Ma
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
(American Association for Cancer Research) Among patients with both colorectal cancer and diabetes in Korea, those who had a high adherence to their oral diabetes medication had a significantly reduced risk of overall mortality compared with those with lower adherence.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Publication date: Available online 30 May 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Deborah Delbue, Bruna S. Mendonça, Marcela C. Robaina, Lauana G.T. Lemos, Pedro I. Lucena, João P.B. Viola, Lídia M. Magalhães, Susanne Crocamo, Caio A.B. Oliveira, Felipe R. Teixeira, Raquel C. Maia, Gabriela Nestal de Moraes
Source: Biochimica et Biophysica Acta (BBA) Molecular Cell Research - Category: Molecular Biology Source Type: research
Publication date: Available online 31 May 2020Source: Journal of Photochemistry and Photobiology B: BiologyAuthor(s): Camila A.P. Monteiro, Aline D.P.R. Oliveira, Ryan C. Silva, Rennan R.M. Lima, Fabricio O. Souto, Mariana O. Baratti, Hernandes F. Carvalho, Beate S. Santos, Paulo E. Cabral Filho, Adriana Fontes
Source: Journal of Photochemistry and Photobiology B: Biology - Category: Speech-Language Pathology Source Type: research
Publication date: Available online 30 May 2020Source: European UrologyAuthor(s): Heidi Fettke, Edmond M. Kwan, Maria M. Docanto, Patricia Bukczynska, Nicole Ng, Lisa-Jane K. Graham, Kate Mahon, Christine Hauser, Winston Tan, Xiao Hong Wang, Zhixin Zhao, Tiantian Zheng, Kemin Zhou, Pan Du, Jianjun Yu, Yong Huang, Shidong Jia, Manish Kohli, Lisa G. Horvath, Arun A. Azad
Source: European Urology - Category: Urology & Nephrology Source Type: research
(Morris Animal Foundation) Morris Animal Foundation has awarded a $775,000 grant to the University of Pennsylvania to test a vaccine that could improve longevity and quality of life for dogs with the deadly bone tumor, osteosarcoma. The research team will conduct clinical trials to evaluate a novel immunotherapy treatment which combines a molecule expressed by cancer cells with a modified live form of the bacteria Listeria monocytogenes.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Aratana Therapeutics Inc.'s cancer immunotherapy drug for dogs gained a conditional license from the U.S. Department of Agriculture, the company announced Wednesday. To gain full licensure, Aratana (Nasdaq; PETX) will start another field study in early 2018. The vaccine initially will be available for purchase at 12 veterinary oncology practices participating in the study. It's designed to treat dogs with bone cancer after the tumor is surgically removed. It works using listeria, a type of bacteria,…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
CONCLUSIONS: These findings demonstrate that ADXS31-164 administered in the setting of minimal residual disease, can induce HER2/neu specific immunity and may reduce the incidence of metastatic disease and prolong overall survival in a clinically relevant, spontaneous, large animal model of cancer. These findings therefore, have important translational relevance for children with osteosarcoma and adults with other HER2/neu+ cancers. PMID: 26994144 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
The purpose of this study is to determine the safety and efficacy of a highly attenuated recombinant Listeria monocytogenes expressing a chimeric human HER2/neu (Lm-LLO-HER2/neu) in combination with palliative radiation (RT) to induce HER2 specific immunity and delay tumor progression in dogs with spontaneous osteosarcoma (OSA). Dogs develop OSA that recapitulates many aspects of human OSA, and are recognized as a clinically relevant, large animal model in which to evaluate novel therapies. Previously we have shown that Lm-LLO-HER2/neu administration to dogs with HER2+ OSA following amputation and chemotherapy is safe, bre...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Clinical Research (Excluding Clinical Trials) Source Type: research
More News: Biotechnology | Bone Cancers | Cancer | Cancer & Oncology | Cancer Vaccines | Health Management | Immunotherapy | Listeria | Study | Vaccines | Veterinary Research | Veterinary Vaccinations